IP Library Granted Patent US 9,605,078
Granted Patent B2
US 9,605,078 · App. 14/443,149 · Granted Mar 28, 2017

Pictet-Spengler ligation for protein chemical modification

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,605,078
App. No.
14/443,149
Granted
Mar 28, 2017
Kind
B2
Abstract

Aldehyde- and ketone-functionalized proteins are promising new substrates for the development of chemically modified biotherapeutics and protein-based materials. Their reactive carbonyl groups are typically conjugated with a-effect nucleophiles, such as substituted hydrazines and alkoxyamines, to generate hydrazones and oximes, respectively. However, the resulting C═N linkages are susceptible to hydrolysis under physiologically relevant conditions, which limits their utility in biological systems. Here we introduce a Pictet-Spengler ligation that is based on the classic Pictet-Spengler reaction of aldehydes and tryptamine nucleophiles. The ligation exploits the bioorthogonal reaction of aldehydes and alkoxyamines to form an intermediate oxyiminium ion; this intermediate undergoes intramolecular C—C bond formation with an indole nucleophile to form an oxacarboline product that is hydrolytically stable. The reaction was utilized for site-specific chemical modification of glyoxal- and formylglycine-functionalized proteins, including an aldehyde-tagged variant of the therapeutic monoclonal antibody Herceptin. In conjunction with techniques for site-specific introduction of aldehydes into proteins, the Pictet-Spengler ligation offers a new means to generate stable bioconjugates for medical and materials applications.

Claims (36)

1. A compound having the formula:

wherein

A is present or absent and, when present, is a substituted or unsubstituted aryl or heteroaryl moiety and R 1 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halogen, CN, CF 3 , acyl, —SO 2 NR 5 R 6 , —NR 5 R 6 , —OR 5 , —S(O) 2 R 5 , —C(O)R 5 , —COOR 5 , —CONR 5 R 6 , —S(O) 2 OR 5 , —OC(O)R 5 , —C(O)NR 5 R 6 , —NR 5 C(O)R 6 , —NR 5 SO 2 R 6 and —NO 2 wherein R 5 and R 6 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl;

R x , R y and R z are selected from H and substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl with the proviso that at least one of R x and R y has a formula selected from:

wherein

R o is unsubstituted alkyl;

wherein

a member selected from R 1 , R x , R y and R z has the formula:

wherein

L is a linker selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and

X is selected from a detectable label, a crosslinking moiety, poly(ethylene glycol) and an affinity label.

2. The compound according to claim 1 , having the formula:

3. The compound according to claim 1 , having a formula selected from:

4. The compound according to claim 1 , wherein said compound has the formula:

wherein

R 1 , R 2 , R 3 , and R 4 are selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halogen, CN, CF 3 , acyl, —SO 2 NR 5 R 6 , —NR 5 R 6 , —OR 5 , —S(O) 2 R 5 , —C(O)R 5 , —COOR 5 , —CONR 5 R 6 , —S(O) 2 OR 5 , —OC(O)R 5 , —C(O)NR 5 R 6 , —NR 5 C(O)R 6 , —NR 5 SO 2 R 6 and —NO 2 , wherein two or more of R 1 , R 2 , R 3 , and R 4 , together with the atoms to which they are bonded, are optionally joined to form a ring system which is a member selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; and

R 5 and R 6 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl.

5. The compound according to claim 1 , wherein L is substituted or unsubstituted alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms.

6. The compound according to claim 1 wherein X is a member selected from a fluorophore and biotin.

7. The compound according to claim 1 , wherein LX has the formula:

wherein

R 7 is selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl; and

n is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10.

8. The compound according to claim 7 , wherein R 7 comprises:

wherein

m is a selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

9. A method of modifying a biomolecule functionalized with a member selected from an aldehyde and a ketone, said method comprising:

(a) contacting said biomolecule with a compound according to claim 1 under reaction conditions appropriate to form a cyclized Pictet-Spengler adduct by reaction of said compound with a moiety selected from said aldehyde and said ketone, thereby modifying said biomolecule.

10. The method according to claim 9 , wherein said adduct has a formula selected from:

wherein

R 1 is selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, halogen, CN, CF 3 , acyl, —SO 2 NR 5 R 6 , —NR 5 R 6 , —OR 5 , —S(O) 2 R 5 , —C(O)R 5 , —COOR 5 , —CONR 5 R 6 , —S(O) 2 OR 5 , —OC(O)R 5 , —C(O)NR 5 R 6 , —NR 5 C(O)R 6 , —NR 5 SO 2 R 6 and —NO 2 , wherein

R 5 and R 6 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted heterocycloalkyl.

11. The method according to claim 9 , wherein said adduct has a formula selected from:

12. The method according to claim 9 , wherein, prior to step (a), a precursor biomolecule is modified with a reactive moiety comprising a member selected from said aldehyde and said ketone, thereby forming said biomolecule functionalized with a member selected from an aldehyde and a ketone.

13. The method of claim 9 wherein said biomolecule is a member selected from a protein, a glycan, a nucleic acid, a metabolite, an inhibitor, a lipid, and a cofactor.

14. The method of claim 9 , wherein said biomolecule is an antibody.

Assignments (5)
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Apr 18, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: WAWONA PACKING CO. LLC; GERAWAN FARMING LLC
Reel/Frame 067165/0022 →
PATENT SECURITY AGREEMENT Recorded Feb 9, 2024
From: WAWONA PACKING CO. LLC; GERAWAN FARMING LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 066550/0539 →
CONVERSION FROM CORPORATION TO LLC Recorded Jan 24, 2024
From: GERAWAN FARMING INC.
To: GERAWAN FARMING LLC
Reel/Frame 066540/0251 →
CONFIRMATORY LICENSE Recorded Apr 18, 2018
From: UNIVERSITY OF CALIFORNIA BERKELEY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045968/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2017
From: SCHUTZ, DENVER FLOYD
To: GERAWAN FARMING, INC.
Reel/Frame 042824/0845 →